Sunshine Biopharma, Inc. (SBFM) Financial Analysis & Valuation | Quarter Chart
Sunshine Biopharma, Inc. (SBFM)
SBFMPrice: $1.1
Fair Value: 🔒
🔒score
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate... more
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the resear... more
Description
Shares
| Market Cap | $5.40M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Drug Manufacturers - Specialty & Generic |
| Country | CA | CEO | Steve N. Slilaty |
| IPO Date | 2022-02-15 | CAGR | — |
| Employees | 52 | Website | www.sunshinebiopharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
SBFM chart loading...
Fundamentals
Technicals
| Enterprise Value | $-11.49M | P/E Ratio | 0.21 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 0.01 | P/B Ratio | 0.01 |
| P/CF Ratio | -0.01 | P/FCF Ratio | -0.01 |
| EPS | $5.31 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 19.22% | Gross Margin | 0.33% |
| Operating Margin | -0.18% | Profit Margin | -0.17% |
| ROE | -0.26% | ROA | -0.2% |
| ROCE | -0.25% | Current Ratio | 5 |
| Quick Ratio | 2.66 | Cash Ratio | 1.85 |
| Debt/Equity | 0.04 | Interest Coverage | 159.76 |
| Altman Z Score | -1.31 | Piotroski Score | 3 |